<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">J. Gastroenterol</journal-id><journal-title-group><journal-title>Journal of Gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">0944-1174</issn><issn pub-type="epub">1435-5922</issn><publisher><publisher-name>Springer Japan</publisher-name><publisher-loc>Tokyo</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24366288</article-id><article-id pub-id-type="pmc">4258614</article-id><article-id pub-id-type="publisher-id">925</article-id><article-id pub-id-type="doi">10.1007/s00535-013-0925-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article&#x02014;Alimentary Tract</subject></subj-group></article-categories><title-group><article-title>A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Nagahara</surname><given-names>Akihito</given-names></name><address><phone>+81-3-58021060</phone><fax>+81-3-38138862</fax><email>nagahara@juntendo.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Suzuki</surname><given-names>Tsuyoshi</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Nagata</surname><given-names>Naoyoshi</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Sugai</surname><given-names>Nozomu</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Takeuchi</surname><given-names>Yoshiaki</given-names></name><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Sakurai</surname><given-names>Kouichi</given-names></name><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Miyamoto</surname><given-names>Masaki</given-names></name><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Inoue</surname><given-names>Kazuhiko</given-names></name><xref ref-type="aff" rid="Aff8"/></contrib><contrib contrib-type="author"><name><surname>Akiyama</surname><given-names>Junichi</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Mabe</surname><given-names>Katsuhiro</given-names></name><xref ref-type="aff" rid="Aff9"/></contrib><contrib contrib-type="author"><name><surname>Konuma</surname><given-names>Ichiro</given-names></name><xref ref-type="aff" rid="Aff10"/></contrib><contrib contrib-type="author"><name><surname>Kamada</surname><given-names>Tomoari</given-names></name><xref ref-type="aff" rid="Aff11"/></contrib><contrib contrib-type="author"><name><surname>Haruma</surname><given-names>Ken</given-names></name><xref ref-type="aff" rid="Aff11"/></contrib><aff id="Aff1"><label/>Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan </aff><aff id="Aff2"><label/>Department of Gastroenterology, Tokyo Metropolitan Police Hospital, Tokyo, Japan </aff><aff id="Aff3"><label/>Department of Gastroenterology and Hepatology, National Center for Global Health and Medicine, Tokyo, Japan </aff><aff id="Aff4"><label/>Department of Gastroenterology, KKR Sapporo Medical Center, Hokkaido, Japan </aff><aff id="Aff5"><label/>Department of Gastroenterology, Showa University School of Medicine, Tokyo, Japan </aff><aff id="Aff6"><label/>Department of Gastroenterology and Hepatology, Kumamoto University, Kumamoto, Japan </aff><aff id="Aff7"><label/>Department of General Internal Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan </aff><aff id="Aff8"><label/>Department of General Medicine, Kawasaki Medical School, Okayama, Japan </aff><aff id="Aff9"><label/>Division of Endoscopy, Hokkaido University Hospital, Hokkaido, Japan </aff><aff id="Aff10"><label/>Konuma Clinic, Tochigi, Japan </aff><aff id="Aff11"><label/>Department of Gastroenterology, Kawasaki Medical School, Okayama, Japan </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>49</volume><issue>12</issue><fpage>1536</fpage><lpage>1547</lpage><history><date date-type="received"><day>15</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>6</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2013</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Proton pump inhibitors (PPIs) are affected by cytochrome P450 2C19 (CYP2C19) polymorphisms. This study compared the effect of two PPIs on early symptom relief in Japanese patients with reflux esophagitis, classified by the CYP2C19 phenotype.</p></sec><sec><title>Methods</title><p>Patients with reflux esophagitis were randomised to treatment with omeprazole 20&#x000a0;mg or rabeprazole 10&#x000a0;mg once daily. The CYP2C19 phenotype [homozygous extensive metaboliser (homoEM), heterozygous extensive metaboliser (heteroEM) or poor metaboliser (PM)] of each patient was determined. The primary efficacy endpoint was early, sufficient (Global Overall Symptom scale score 1 or 2), sustained (maintained for &#x02265;7&#x000a0;days) reflux symptom relief.</p></sec><sec><title>Results</title><p>Of the 199 patients included in this analysis, the proportion achieving sufficient, sustained reflux symptom relief was higher with omeprazole than with rabeprazole on day&#x000a0;1 (35.6 vs. 22.4&#x000a0;%; <italic>p</italic>&#x000a0;=&#x000a0;0.041) and day&#x000a0;2 (43.6 vs. 28.6&#x000a0;%; <italic>p</italic>&#x000a0;=&#x000a0;0.028); there was no significant difference between the two groups on days&#x000a0;3&#x02013;7. Among patients with the CYP2C19 PM phenotype, sufficient, sustained reflux symptom relief was higher with omeprazole than with rabeprazole on days&#x000a0;4&#x02013;7 (62.5&#x02013;66.9 vs 31.6&#x000a0;%; <italic>p</italic>&#x000a0;&#x02264;&#x000a0;0.03); differences were not significant on days 1&#x02013;3, or among those with the homoEM or heteroEM phenotypes on days&#x000a0;1&#x02013;7.</p></sec><sec><title>Conclusions</title><p>In Japanese patients with reflux esophagitis, omeprazole 20&#x000a0;mg is more effective than rabeprazole 10&#x000a0;mg at achieving early, sufficient, sustained reflux symptom relief in individuals with the CYP2C19 PM phenotype, and is similarly effective to rabeprazole 10&#x000a0;mg in those with heteroEM or homoEM phenotypes.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Omeprazole</kwd><kwd>Rabeprazole</kwd><kwd>Proton pump inhibitor</kwd><kwd>Reflux esophagitis</kwd><kwd>Symptom relief</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Japan 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="intro"><title>Introduction</title><p>Gastroesophageal reflux disease (GERD) is characterised by reflux of the stomach contents and/or bile into the esophagus [<xref ref-type="bibr" rid="CR1">1</xref>], typically causing symptoms of heartburn and acid regurgitation [<xref ref-type="bibr" rid="CR2">2</xref>]. Studies conducted in Japan have found that between 6.5 and 9.5&#x000a0;% of the population have reflux symptoms on at least 1&#x000a0;day per week, and the reported prevalence of reflux esophagitis ranges from 4.9 to 8.2&#x000a0;% [<xref ref-type="bibr" rid="CR3">3</xref>]. Various lifestyle factors are reported to be associated with GERD [<xref ref-type="bibr" rid="CR4">4</xref>], and reflux symptoms negatively affect health-related quality of life, work productivity, and health resource utilisation [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. Moreover, reflux esophagitis is a risk factor for Barrett&#x02019;s esophagus and esophageal adenocarcinoma [<xref ref-type="bibr" rid="CR9">9</xref>]. Proton pump inhibitors (PPIs) are the most effective treatment for GERD, including endoscopically confirmed reflux esophagitis [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Most individuals experience resolution of their reflux symptoms when taking a PPI [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], with a concomitant overall improvement in health-related quality of life [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p>PPIs are metabolised via the hepatic enzyme cytochrome P450 2C19 (CYP2C19). There are three genetic polymorphisms of CYP2C19, resulting in homozygous extensive metaboliser (homoEM), heterozygous extensive metaboliser (heteroEM) and poor metaboliser (PM) phenotypes [<xref ref-type="bibr" rid="CR13">13</xref>]. These CYP2C19 phenotypes have different effects on the pharmacodynamic and pharmacokinetic profiles of PPIs. Gastric acid secretion is affected such that post-PPI intragastric pH values are highest in the PM group and lowest in the homoEM group following administration of omeprazole or rabeprazole [<xref ref-type="bibr" rid="CR14">14</xref>]. The clinical relevance of these differences is especially important for patients in Japan, where the PM phenotype is much more common (prevalence 18.0&#x02013;22.5&#x000a0;%) than in the USA or Europe (prevalence &#x02264;3.7&#x000a0;%) [<xref ref-type="bibr" rid="CR13">13</xref>].</p><p>Results from studies in healthy Japanese volunteers suggest that early effects on gastric acid inhibition in people with different CYP2C19 phenotypes may depend on the type of PPI used [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR17">17</xref>]. Compared with omeprazole 20&#x000a0;mg or lansoprazole 30&#x000a0;mg, rabeprazole&#x000a0;10&#x000a0;mg has been shown to exert a faster and more pronounced inhibition of gastric acid secretion in healthy Japanese volunteers with the homoEM or heteroEM phenotypes [<xref ref-type="bibr" rid="CR15">15</xref>]; however, in another study also conducted in healthy Japanese volunteers with the homoEM or heteroEM phenotypes, lansoprazole 30&#x000a0;mg was shown to induce an earlier rise in blood PPI concentration and intragastric pH than rabeprazole 10&#x000a0;mg [<xref ref-type="bibr" rid="CR16">16</xref>]. Furthermore, in healthy Japanese volunteers receiving omeprazole 20&#x000a0;mg or rabeprazole 10&#x000a0;mg, there was no significant difference between the two PPIs in early intragastric pH changes in individuals with the homoEM phenotype, but intragastric pH was significantly higher with omeprazole than with rabeprazole 6&#x02013;8&#x000a0;h after PPI administration according to combined data from participants with the heteroEM and PM phenotypes [<xref ref-type="bibr" rid="CR17">17</xref>]. Thus, whereas the pharmacodynamic and pharmacokinetic profiles of omeprazole and rabeprazole are clearly dependent on CYP2C19 phenotype, data from healthy volunteers on differences in early acid inhibitory effects between the two PPIs are inconsistent. In addition, there is a paucity of data on whether any differences in early acid inhibitory effects in healthy volunteers translate into early differences in clinical outcomes in patients with GERD.</p><p>We conducted this study to compare the efficacy of omeprazole 20&#x000a0;mg and rabeprazole 10&#x000a0;mg in achieving early symptom relief in Japanese patients with reflux esophagitis. Our analysis took into consideration outcomes based on CYP2C19 phenotype.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>This was a 4-week, multicentre, randomised, open-label, parallel-group study conducted at 18 centres in Japan between January 2010 and March 2011. Eligible patients were randomly allocated by the study coordination centre (five patients per block per study centre) to receive omeprazole 20&#x000a0;mg or rabeprazole 10&#x000a0;mg orally once daily (in the morning) for 4&#x000a0;weeks. Participants were asked to complete the investigator-administered Global Overall Symptom (GOS) scale to determine symptom severity at baseline (screening visit) and at the end of 2 and 4&#x000a0;weeks of PPI therapy. In addition, participants used the GOS scale to record the severity of their reflux symptoms (heartburn and acid regurgitation) in a daily diary (before bedtime) during the first 2&#x000a0;weeks of the study. An overview of the study design is provided in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Overview of study design. <italic>GOS</italic> Global Overall Symptom</p></caption><graphic xlink:href="535_2013_925_Fig1_HTML" id="MO1"/></fig></p><p>Eligible participants were also asked to provide two 5&#x000a0;mL blood samples at screening to determine their <italic>Helicobacter pylori</italic> status (assessed using enzyme immunoassay) and CYP2C19 phenotype (homoEM, heteroEM or PM; assessed using gene analysis by fluorescence correlation spectroscopy).</p><p>The study protocol was reviewed and approved by the ethics review boards of all participating centres before the start of the investigation. The study was conducted in accordance with the principles of the Declaration of Helsinki and all patients provided informed consent as a condition of participation.</p></sec><sec id="Sec4"><title>Patients</title><p>Patients of either sex aged 20&#x000a0;years and older were eligible for inclusion if they had diagnoses of reflux esophagitis (Los Angeles grades A&#x02013;D) on endoscopy during the preceding 12&#x000a0;months. Individuals also had to have heartburn and/or acid regurgitation of at least moderate severity (GOS scale score &#x02265;4) at baseline (screening visit).</p><p>Exclusion criteria were: &#x02018;alarm&#x02019; features (e.g. vomiting, gastrointestinal haemorrhage and involuntary weight loss); peptic ulcer (other than those at the scarred stage); history of gastrointestinal resection or vagotomy; history of inflammatory bowel disease, irritable bowel syndrome, esophageal stenosis, esophageal achalasia, Zollinger&#x02013;Ellison syndrome, malabsorption or cerebral disorders; serious hepatic, renal or cardiac disease; confirmed or suspected malignancies; or requirement for continued use of medication that might interact with the test drugs (e.g. atazanavir sulphate, diazepam, phenytoin, warfarin, tacrolimus hydrate, digoxin, methyldigoxin, itraconazole, gefitinib, voriconazole, acid suppressants containing aluminium hydroxide gel, or magnesium hydroxide). Women who were or might have been pregnant, or who were lactating, were also excluded from the study.</p><p>The following medications were discontinued at least 1&#x000a0;week before study entry and were not allowed during the study period: PPIs (other than the study PPIs), histamine-2 receptor antagonists, prokinetic agents, gastric mucosal protective agents, anticholinergic drugs, antidepressants, anxiolytics, antidiabetic agents, steroids (other than topical steroids), non-steroidal anti-inflammatory drugs [including acetylsalicylic acid (ASA) preparations and low-dose ASA], and bisphosphonates.</p></sec><sec id="Sec5"><title>Efficacy assessments</title><p>The efficacy of omeprazole 20&#x000a0;mg and rabeprazole 10&#x000a0;mg was assessed on the basis of the GOS scale heartburn and acid regurgitation scores recorded by patients in their daily diary entries during the first 2&#x000a0;weeks, and from the GOS scale that was completed at the clinic after 2 and 4&#x000a0;weeks of PPI therapy.</p><p>The GOS scale has been validated for the assessment of upper gastrointestinal symptoms in the clinical trial setting [<xref ref-type="bibr" rid="CR18">18</xref>], and has been used in clinical studies to assess symptoms of GERD (heartburn and acid regurgitation) and other upper gastrointestinal symptoms [<xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>]. The GOS scale measures the severity of eight symptoms (heartburn, acid regurgitation, gastric pain, stomach feeling heavy, early satiety, feeling queasy, burping and feeling of fullness) on a 7-point scale, from 1 [&#x02018;no problem&#x02019; (no symptoms)] to 7 [&#x02018;very severe problem&#x02019; (cannot be ignored and markedly limits my daily activities and often requires rest)] [<xref ref-type="bibr" rid="CR18">18</xref>]. The GOS scale was used in the current study to perform symptom-based evaluations, not to diagnose reflux esophagitis. Therefore, no cut-off value was implemented in this study.</p></sec><sec id="Sec6"><title>Primary and secondary endpoints</title><p>The primary efficacy endpoint was the proportion of patients who had sufficient and sustained (for &#x02265;7 consecutive days) relief of reflux symptoms, defined as the first day of PPI therapy on which the GOS scale score was 1 [&#x02018;no problem&#x02019; (no symptoms)] or 2 [&#x02018;minimal problem (can be easily ignored without effort)&#x02019;]. Secondary efficacy endpoints included the proportion of patients who had: sufficient and sustained relief of reflux symptoms assessed by CYP2C19 phenotype; sufficient relief of reflux symptoms (GOS scale score of 1 or 2) after 2 and 4&#x000a0;weeks of PPI therapy (overall and by CYP2C19 phenotype); sufficient relief of upper gastrointestinal symptoms (GOS scale score of 1 or 2) after 2 and 4&#x000a0;weeks of PPI therapy (overall and by CYP2C19 phenotype); complete resolution of reflux symptoms (GOS scale score of 1) after 2 and 4&#x000a0;weeks of PPI therapy (overall and by CYP2C19 phenotype); and complete resolution of upper gastrointestinal symptoms (GOS scale score of 1) after 2 and 4&#x000a0;weeks of PPI therapy (overall and by CYP2C19 phenotype).</p></sec><sec id="Sec7"><title>Safety assessments</title><p>Adverse events were recorded throughout the study period and were assessed according to whether or not they were serious, their relationship to the study drug, their time of onset, and the outcome. All adverse events were reported descriptively.</p></sec><sec id="Sec8"><title>Statistical analyses</title><sec id="Sec9"><title>Sample size</title><p>The median time to reach heartburn control was estimated to be 2&#x000a0;days for the omeprazole 20&#x000a0;mg group and 3&#x000a0;days for the rabeprazole 10&#x000a0;mg group, based on data by Bytzer et al. [<xref ref-type="bibr" rid="CR22">22</xref>], and taking into consideration the distribution of the different phenotypes and the treatment doses. Based on these median times, the proportion of patients with symptom improvement was estimated to be 90&#x000a0;% in the omeprazole 20&#x000a0;mg group and 77&#x000a0;% in the rabeprazole 10&#x000a0;mg group. Using these criteria, 97 patients were required to participate in the study to detect a 5&#x000a0;% (two-sided) inter-group difference in the primary variable using the log-rank test. A dropout rate of approximately 10&#x000a0;% was assumed; thus, the plan was to enrol approximately 220 patients (110 per group).</p></sec><sec id="Sec10"><title>Efficacy and safety variables</title><p>The primary and secondary efficacy endpoints were analysed using data from all patients with at least one assessment of efficacy after the initiation of study treatment.</p><p>Sufficient symptom relief was defined as a score of 1 or 2 on the GOS scale, and complete symptom resolution was defined as a score of 1 on the GOS scale. Sufficient and sustained symptom relief was defined as maintenance of sufficient symptom relief for at least 7&#x000a0;consecutive days. Inter-group differences in the proportion of patients reaching the primary and secondary endpoints were analysed using the <italic>&#x003c7;</italic><sup>2</sup> test, with statistical significance defined as <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 (two-sided).</p></sec></sec></sec><sec id="Sec11" sec-type="results"><title>Results</title><sec id="Sec12"><title>Patient population</title><p>In total, 209 eligible patients with reflux esophagitis were randomised and received at least one dose of omeprazole 20&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;106) or rabeprazole 10&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;103). Evaluable data were available for 101 patients (95.3&#x000a0;%) in the omeprazole 20&#x000a0;mg group and 98&#x000a0;patients (95.1&#x000a0;%) in the rabeprazole 10&#x000a0;mg group. Ten patients (4.8&#x000a0;%) were excluded from the efficacy analysis because they did not provide daily diary records.</p><p>All patients included in this analysis had heartburn and/or acid regurgitation of at least moderate severity (GOS scale score &#x02265;4) at baseline, in accordance with study inclusion criteria. Baseline demographics and clinical characteristics are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>; there were no significant differences between the two treatment groups. Mean GOS scale scores at baseline were similar in the two treatment groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Baseline demographics and clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Omeprazole (<italic>n</italic>&#x000a0;=&#x000a0;101)</th><th align="left">Rabeprazole (<italic>n</italic>&#x000a0;=&#x000a0;98)</th><th align="left">Total (<italic>N</italic>&#x000a0;=&#x000a0;199)</th><th align="left">
<italic>p</italic> value<sup>a</sup>
</th></tr></thead><tbody><tr><td align="left" colspan="5">Sex</td></tr><tr><td align="left">&#x000a0;Male</td><td align="left">54 (53.5)</td><td align="left">58 (59.2)</td><td align="left">112 (56.3)</td><td char="." align="char" rowspan="2">0.416</td></tr><tr><td align="left">&#x000a0;Female</td><td align="left">47 (46.5)</td><td align="left">40 (40.8)</td><td align="left">87 (43.7)</td></tr><tr><td align="left" colspan="5">Age, years</td></tr><tr><td align="left">&#x000a0;29</td><td align="left">3 (3.0)</td><td align="left">2 (2.0)</td><td align="left">5 (2.5)</td><td char="." align="char" rowspan="6">0.970</td></tr><tr><td align="left">&#x000a0;30&#x02013;39</td><td align="left">11 (10.9)</td><td align="left">11 (11.2)</td><td align="left">22 (11.1)</td></tr><tr><td align="left">&#x000a0;40&#x02013;49</td><td align="left">16 (15.8)</td><td align="left">20 (20.4)</td><td align="left">36 (18.1)</td></tr><tr><td align="left">&#x000a0;50&#x02013;59</td><td align="left">26 (25.7)</td><td align="left">23 (23.5)</td><td align="left">49 (24.6)</td></tr><tr><td align="left">&#x000a0;60&#x02013;69</td><td align="left">25 (24.8)</td><td align="left">24 (24.5)</td><td align="left">49 (24.6)</td></tr><tr><td align="left">&#x000a0;70</td><td align="left">20 (19.8)</td><td align="left">18 (18.4)</td><td align="left">38 (19.1)</td></tr><tr><td align="left">&#x000a0;Mean&#x000a0;&#x000b1;&#x000a0;SD</td><td char="&#x000b1;" align="char">56.8&#x000a0;&#x000b1;&#x000a0;11.2</td><td char="&#x000b1;" align="char">55.8&#x000a0;&#x000b1;&#x000a0;11.3</td><td char="&#x000b1;" align="char">56.3&#x000a0;&#x000b1;&#x000a0;13.7</td><td align="left"/></tr><tr><td align="left" colspan="5">BMI, kg/m<sup>2</sup>
</td></tr><tr><td char="." align="char">&#x000a0;&#x0003c;25</td><td align="left">60 (59.4)</td><td align="left">63 (64.3)</td><td align="left">123 (61.8)</td><td char="." align="char" rowspan="2">0.468</td></tr><tr><td align="left">&#x000a0;&#x02265;25</td><td align="left">39 (38.6)</td><td align="left">33 (33.8)</td><td align="left">72 (36.2)</td></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">2 (2.0)</td><td align="left">2 (2.0)</td><td align="left">4 (2.0)</td><td align="left"/></tr><tr><td align="left" colspan="5">Reflux esophagitis, LA grade</td></tr><tr><td align="left">&#x000a0;A</td><td align="left">55 (54.5)</td><td align="left">68 (69.4)</td><td align="left">123 (61.8)</td><td char="." align="char" rowspan="4">0.220</td></tr><tr><td align="left">&#x000a0;B</td><td align="left">34 (33.7)</td><td align="left">23 (23.5)</td><td align="left">57 (28.6)</td></tr><tr><td align="left">&#x000a0;C</td><td align="left">9 (8.9)</td><td align="left">6 (6.1)</td><td align="left">15 (7.5)</td></tr><tr><td align="left">&#x000a0;D</td><td align="left">2 (2.0)</td><td align="left">1 (1.0)</td><td align="left">3 (1.5)</td></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">1 (1.0)</td><td align="left">0 (0.0)</td><td align="left">1 (0.5)</td><td align="left"/></tr><tr><td align="left" colspan="5">
<italic>Helicobacter pylori</italic> test</td></tr><tr><td align="left">&#x000a0;Negative</td><td align="left">76 (75.2)</td><td align="left">65 (66.3)</td><td align="left">141 (70.9)</td><td char="." align="char" rowspan="2">0.168</td></tr><tr><td align="left">&#x000a0;Positive</td><td align="left">9 (8.9)</td><td align="left">19 (19.4)</td><td align="left">28 (14.1)</td></tr><tr><td align="left">&#x000a0;Judgement impossible</td><td align="left">1 (1.0)</td><td align="left">2 (2.0)</td><td align="left">3 (1.5)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">15 (14.9)</td><td align="left">12 (12.2)</td><td align="left">27 (13.6)</td><td align="left"/></tr><tr><td align="left" colspan="5">CYP2C19 test</td></tr><tr><td align="left">&#x000a0;HomoEM</td><td align="left">36 (35.6)</td><td align="left">37 (37.8)</td><td align="left">73 (36.7)</td><td char="." align="char" rowspan="3">0.803</td></tr><tr><td align="left">&#x000a0;HeteroEM</td><td align="left">40 (39.6)</td><td align="left">42 (42.9)</td><td align="left">82 (41.2)</td></tr><tr><td align="left">&#x000a0;PM</td><td align="left">23 (22.8)</td><td align="left">19 (19.4)</td><td align="left">42 (21.1)</td></tr><tr><td align="left">&#x000a0;Unknown</td><td align="left">2 (2.0)</td><td align="left">0 (0.0)</td><td align="left">2 (1.0)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Data presented as <italic>n</italic> (%) unless otherwise indicated</p><p>
<italic>BMI</italic> body mass index, <italic>CYP2C19</italic> cytochrome P450 2C19, <italic>heteroEM</italic> hetero extensive metaboliser, <italic>homoEM</italic> homo extensive metaboliser, <italic>LA</italic> Los Angeles, <italic>PM</italic> poor metaboliser, <italic>SD</italic> standard deviation</p><p>
<sup>a</sup>Excluding unknown and judgement impossible</p></table-wrap-foot></table-wrap><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Baseline Global Overall Symptom scale scores</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">GOS scale score</th><th align="left">Omeprazole (<italic>n</italic>&#x000a0;=&#x000a0;101)</th><th align="left">Rabeprazole (<italic>n</italic>&#x000a0;=&#x000a0;98)</th><th align="left">Total (<italic>N</italic>&#x000a0;=&#x000a0;199)</th><th align="left">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="5">Heartburn</td></tr><tr><td align="left">&#x000a0;7</td><td align="left">4 (4.0)</td><td align="left">2 (2.0)</td><td align="left">6 (3.0)</td><td char="." align="char" rowspan="7">0.448</td></tr><tr><td align="left">&#x000a0;6</td><td align="left">13 (12.9)</td><td align="left">12 (12.2)</td><td align="left">25 (12.6)</td></tr><tr><td align="left">&#x000a0;5</td><td align="left">28 (27.7)</td><td align="left">24 (24.5)</td><td align="left">52 (26.1)</td></tr><tr><td align="left">&#x000a0;4</td><td align="left">37 (36.6)</td><td align="left">39 (39.8)</td><td align="left">76 (38.2)</td></tr><tr><td align="left">&#x000a0;3</td><td align="left">8 (7.9)</td><td align="left">12 (12.2)</td><td align="left">20 (10.1)</td></tr><tr><td align="left">&#x000a0;2</td><td align="left">8 (7.9)</td><td align="left">6 (6.1)</td><td align="left">14 (7.0)</td></tr><tr><td align="left">&#x000a0;1</td><td align="left">3 (3.0)</td><td align="left">3 (3.1)</td><td align="left">6 (3.0)</td></tr><tr><td align="left">&#x000a0;Mean&#x000a0;&#x000b1;&#x000a0;SD</td><td align="left">4.3 (1.5)</td><td align="left">4.2 (0.9)</td><td align="left">4.3 (1.3)</td><td align="left"/></tr><tr><td align="left" colspan="5">Sensation of reflux of gastric acid</td></tr><tr><td align="left">&#x000a0;7</td><td align="left">6 (5.9)</td><td align="left">1 (1.0)</td><td align="left">7 (3.5)</td><td char="." align="char" rowspan="7">0.337</td></tr><tr><td align="left">&#x000a0;6</td><td align="left">11 (10.9)</td><td align="left">11 (11.2)</td><td align="left">22 (11.1)</td></tr><tr><td align="left">&#x000a0;5</td><td align="left">18 (17.8)</td><td align="left">14 (14.3)</td><td align="left">32 (16.1)</td></tr><tr><td align="left">&#x000a0;4</td><td align="left">29 (28.7)</td><td align="left">35 (35.7)</td><td align="left">64 (32.2)</td></tr><tr><td align="left">&#x000a0;3</td><td align="left">16 (15.8)</td><td align="left">14 (14.3)</td><td align="left">30 (15.1)</td></tr><tr><td align="left">&#x000a0;2</td><td align="left">18 (17.8)</td><td align="left">14 (14.3)</td><td align="left">32 (16.1)</td></tr><tr><td align="left">&#x000a0;1</td><td align="left">3 (3.0)</td><td align="left">8 (8.2)</td><td align="left">11 (5.5)</td></tr><tr><td align="left">&#x000a0;Mean&#x000a0;&#x000b1;&#x000a0;SD</td><td char="&#x000b1;" align="char">4.0&#x000a0;&#x000b1;&#x000a0;1.2</td><td char="&#x000b1;" align="char">3.7&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="left">3.9 (1.5)</td><td align="left"/></tr><tr><td align="left" colspan="5">Gastric pain</td></tr><tr><td align="left">&#x000a0;7</td><td align="left">4 (4.0)</td><td align="left">1 (1.0)</td><td align="left">5 (2.5)</td><td char="." align="char" rowspan="7">0.835</td></tr><tr><td align="left">&#x000a0;6</td><td align="left">5 (5.0)</td><td align="left">4 (4.1)</td><td align="left">9 (4.5)</td></tr><tr><td align="left">&#x000a0;5</td><td align="left">10 (9.9)</td><td align="left">10 (10.2)</td><td align="left">20 (10.1)</td></tr><tr><td align="left">&#x000a0;4</td><td align="left">13 (12.9)</td><td align="left">15 (15.3)</td><td align="left">28 (14.1)</td></tr><tr><td align="left">&#x000a0;3</td><td align="left">16 (15.8)</td><td align="left">22 (22.4)</td><td align="left">38 (19.1)</td></tr><tr><td align="left">&#x000a0;2</td><td align="left">18 (17.8)</td><td align="left">14 (14.3)</td><td align="left">32 (16.1)</td></tr><tr><td align="left">&#x000a0;1</td><td align="left">35 (34.7)</td><td align="left">31 (31.6)</td><td align="left">66 (33.2)</td></tr><tr><td align="left">&#x000a0;Mean&#x000a0;&#x000b1;&#x000a0;SD</td><td char="&#x000b1;" align="char">2.8&#x000a0;&#x000b1;&#x000a0;1.5</td><td char="&#x000b1;" align="char">2.7&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="left">2.8 (1.7)</td><td align="left"/></tr><tr><td align="left" colspan="5">Stomach feeling heavy</td></tr><tr><td char="." align="char">&#x000a0;7</td><td align="left">1 (1.0)</td><td align="left">0 (0.0)</td><td align="left">1 (0.5)</td><td char="." align="char" rowspan="7">0.399</td></tr><tr><td char="." align="char">&#x000a0;6</td><td align="left">5 (5.0)</td><td align="left">4 (4.1)</td><td align="left">9 (4.5)</td></tr><tr><td char="." align="char">&#x000a0;5</td><td align="left">13 (12.9)</td><td align="left">16 (16.3)</td><td align="left">29 (14.6)</td></tr><tr><td char="." align="char">&#x000a0;4</td><td align="left">16 (15.8)</td><td align="left">23 (23.5)</td><td align="left">39 (19.6)</td></tr><tr><td char="." align="char">&#x000a0;3</td><td align="left">25 (24.8)</td><td align="left">20 (20.4)</td><td align="left">45 (22.6)</td></tr><tr><td char="." align="char">&#x000a0;2</td><td align="left">23 (22.8)</td><td align="left">17 (17.3)</td><td align="left">40 (20.1)</td></tr><tr><td char="." align="char">&#x000a0;1</td><td align="left">18 (17.8)</td><td align="left">17 (17.3)</td><td align="left">35 (17.6)</td></tr><tr><td align="left">&#x000a0;Mean&#x000a0;&#x000b1;&#x000a0;SD</td><td char="&#x000b1;" align="char">3.0&#x000a0;&#x000b1;&#x000a0;1.2</td><td char="&#x000b1;" align="char">3.2&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="left">3.1 (1.5)</td><td align="left"/></tr><tr><td align="left" colspan="5">Feeling queasy</td></tr><tr><td char="." align="char">&#x000a0;7</td><td align="left">2 (2.0)</td><td align="left">1 (1.0)</td><td align="left">3 (1.5)</td><td char="." align="char" rowspan="7">0.801</td></tr><tr><td char="." align="char">&#x000a0;6</td><td align="left">4 (4.0)</td><td align="left">4 (4.1)</td><td align="left">8 (4.0)</td></tr><tr><td char="." align="char">&#x000a0;5</td><td align="left">6 (6.0)</td><td align="left">5 (5.1)</td><td align="left">11 (5.5)</td></tr><tr><td char="." align="char">&#x000a0;4</td><td align="left">11 (10.9)</td><td align="left">9 (9.2)</td><td align="left">20 (10.1)</td></tr><tr><td char="." align="char">&#x000a0;3</td><td align="left">9 (8.9)</td><td align="left">11 (11.2)</td><td align="left">20 (10.1)</td></tr><tr><td char="." align="char">&#x000a0;2</td><td align="left">19 (18.8)</td><td align="left">18 (18.4)</td><td align="left">37 (36.6)</td></tr><tr><td char="." align="char">&#x000a0;1</td><td align="left">50 (49.5)</td><td align="left">49 (50.0)</td><td align="left">99 (98.0)</td></tr><tr><td align="left">&#x000a0;Mean&#x000a0;&#x000b1;&#x000a0;SD</td><td char="&#x000b1;" align="char">2.2&#x000a0;&#x000b1;&#x000a0;1.3</td><td char="&#x000b1;" align="char">2.2&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="left">2.2 (1.6)</td><td align="left"/></tr><tr><td align="left" colspan="5">Burping</td></tr><tr><td char="." align="char">&#x000a0;7</td><td align="left">1 (1.0)</td><td align="left">1 (1.0)</td><td align="left">2 (1.0)</td><td char="." align="char" rowspan="7">0.387</td></tr><tr><td char="." align="char">&#x000a0;6</td><td align="left">3 (3.0)</td><td align="left">3 (3.1)</td><td align="left">6 (3.0)</td></tr><tr><td char="." align="char">&#x000a0;5</td><td align="left">14 (13.9)</td><td align="left">14 (14.3)</td><td align="left">28 (14.1)</td></tr><tr><td char="." align="char">&#x000a0;4</td><td align="left">11 (10.9)</td><td align="left">9 (9.2)</td><td align="left">20 (10.1)</td></tr><tr><td char="." align="char">&#x000a0;3</td><td align="left">14 (13.9)</td><td align="left">22 (22.4)</td><td align="left">36 (18.1)</td></tr><tr><td char="." align="char">&#x000a0;2</td><td align="left">30 (29.7)</td><td align="left">27 (27.6)</td><td align="left">57 (28.6)</td></tr><tr><td char="." align="char">&#x000a0;1</td><td align="left">28 (27.7)</td><td align="left">21 (21.4)</td><td align="left">49 (24.6)</td></tr><tr><td align="left">&#x000a0;Mean&#x000a0;&#x000b1;&#x000a0;SD</td><td char="&#x000b1;" align="char">2.7&#x000a0;&#x000b1;&#x000a0;1.3</td><td char="&#x000b1;" align="char">2.8&#x000a0;&#x000b1;&#x000a0;1.2</td><td align="left">2.7 (1.5)</td><td align="left"/></tr><tr><td align="left" colspan="5">Early satiety</td></tr><tr><td char="." align="char">&#x000a0;7</td><td align="left">3 (3.0)</td><td align="left">0 (0.0)</td><td align="left">3 (1.5)</td><td char="." align="char" rowspan="7">0.092</td></tr><tr><td char="." align="char">&#x000a0;6</td><td align="left">1 (1.0)</td><td align="left">1 (1.0)</td><td align="left">2 (1.0)</td></tr><tr><td char="." align="char">&#x000a0;5</td><td align="left">8 (7.9)</td><td align="left">4 (4.1)</td><td align="left">12 (6.0)</td></tr><tr><td char="." align="char">&#x000a0;4</td><td align="left">16 (15.8)</td><td align="left">18 (18.4)</td><td align="left">34 (17.1)</td></tr><tr><td char="." align="char">&#x000a0;3</td><td align="left">21 (20.8)</td><td align="left">14 (14.3)</td><td align="left">35 (17.6)</td></tr><tr><td char="." align="char">&#x000a0;2</td><td align="left">24 (23.8)</td><td align="left">23 (23.5)</td><td align="left">47 (23.6)</td></tr><tr><td char="." align="char">&#x000a0;1</td><td align="left">28 (27.7)</td><td align="left">37 (37.8)</td><td align="left">65 (32.7)</td></tr><tr><td align="left">&#x000a0;Mean&#x000a0;&#x000b1;&#x000a0;SD</td><td char="&#x000b1;" align="char">2.7&#x000a0;&#x000b1;&#x000a0;1.2</td><td char="&#x000b1;" align="char">2.3&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="left">2.5 (1.4)</td><td align="left"/></tr><tr><td align="left" colspan="5">Feeling of fullness</td></tr><tr><td char="." align="char">&#x000a0;7</td><td align="left">3 (3.0)</td><td align="left">0 (0.0)</td><td align="left">3 (1.5)</td><td char="." align="char" rowspan="7">0.565</td></tr><tr><td char="." align="char">&#x000a0;6</td><td align="left">4 (4.0)</td><td align="left">3 (3.1)</td><td align="left">7 (3.5)</td></tr><tr><td char="." align="char">&#x000a0;5</td><td align="left">6 (6.0)</td><td align="left">9 (9.2)</td><td align="left">15 (7.5)</td></tr><tr><td char="." align="char">&#x000a0;4</td><td align="left">18 (17.8)</td><td align="left">16 (16.3)</td><td align="left">34 (17.1)</td></tr><tr><td char="." align="char">&#x000a0;3</td><td align="left">18 (17.8)</td><td align="left">14 (14.3)</td><td align="left">32 (16.1)</td></tr><tr><td char="." align="char">&#x000a0;2</td><td align="left">23 (22.8)</td><td align="left">25 (25.5)</td><td align="left">48 (24.1)</td></tr><tr><td char="." align="char">&#x000a0;1</td><td align="left">29 (28.7)</td><td align="left">30 (30.6)</td><td align="left">59 (29.6)</td></tr><tr><td align="left">&#x000a0;Mean&#x000a0;&#x000b1;&#x000a0;SD</td><td char="&#x000b1;" align="char">2.7&#x000a0;&#x000b1;&#x000a0;1.3</td><td char="&#x000b1;" align="char">2.6&#x000a0;&#x000b1;&#x000a0;1.3</td><td align="left">2.7 (1.5)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Data presented as <italic>n</italic> (%) unless otherwise indicated</p><p>Symptoms are evaluated on the 7-point GOS scale, from 1 [&#x02018;no problem&#x02019; (no symptoms)] to 7 [&#x02018;very severe problem&#x02019; (cannot be ignored and markedly limits my daily activities and often requires rest)]</p><p>
<italic>GOS</italic> Global Overall Symptom, <italic>SD</italic> standard deviation</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Efficacy</title><sec id="Sec14"><title>Primary efficacy endpoint</title><p>On day&#x000a0;1 of PPI therapy, the proportion of patients achieving sufficient and sustained relief of their reflux symptoms for at least 7 consecutive days was 35.6&#x000a0;% with omeprazole 20&#x000a0;mg and 22.4&#x000a0;% with rabeprazole 10&#x000a0;mg (<italic>p</italic>&#x000a0;=&#x000a0;0.041; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). On day&#x000a0;2 of PPI therapy, it was 43.6&#x000a0;% with omeprazole 20&#x000a0;mg and 28.6&#x000a0;% with rabeprazole 10&#x000a0;mg (<italic>p</italic>&#x000a0;=&#x000a0;0.028; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Sufficient and sustained relief of reflux symptoms continued to be observed in a greater proportion of patients in the omeprazole 20&#x000a0;mg group (46.5&#x02013;61.4&#x000a0;%) than in the rabeprazole 10&#x000a0;mg group (39.8&#x02013;52.0&#x000a0;%) on days 3&#x02013;7, but the difference between the two groups was no longer statistically significant.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Proportion of patients achieving sustained and sufficient relief of their reflux symptoms on days&#x000a0;1&#x02013;7 of therapy with omeprazole 20&#x000a0;mg or rabeprazole 10&#x000a0;mg. Sustained and sufficient symptom relief was defined as a GOS scale score of 1 or 2 that was maintained for at least 7&#x000a0;consecutive days. <italic>GOS</italic> Global Overall Symptom</p></caption><graphic xlink:href="535_2013_925_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec15"><title>Secondary efficacy endpoints</title><p>Among patients with the PM phenotype, a greater proportion in the omeprazole 20&#x000a0;mg than in the rabeprazole 10&#x000a0;mg group achieved sufficient and sustained relief of their reflux symptoms on days&#x000a0;1&#x02013;7 of PPI therapy; between-group differences reached statistical significance on days 4&#x02013;7 (omeprazole 62.5&#x02013;66.9&#x000a0;% vs rabeprazole 31.6&#x000a0;%; <italic>p</italic>&#x000a0;&#x02264;&#x000a0;0.03; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a). Sufficient and sustained relief of reflux symptoms on days&#x000a0;1&#x02013;7 of PPI therapy was not statistically different in the omeprazole 20&#x000a0;mg and the rabeprazole 10 mg groups in patients with either the homoEM or heteroEM phenotypes (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b, c).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Proportion of patients achieving sustained and sufficient relief of their reflux symptoms on days&#x000a0;1&#x02013;7 of therapy with omeprazole 20&#x000a0;mg or rabeprazole 10&#x000a0;mg in those with the CYP2C19 phenotype <bold>a</bold> PM, <bold>b</bold> heteroEM and <bold>c</bold> homoEM. Sustained and sufficient symptom relief was defined as a GOS scale score of 1 or 2 that was maintained for at least 7&#x000a0;consecutive days. CYP2C19 phenotype was unknown for two patients in the omeprazole group. <italic>CYP2C19</italic> cytochrome P450 2C19, <italic>GOS</italic> Global Overall Symptom, <italic>heteroEM</italic> hetero extensive metaboliser, <italic>homoEM</italic> homo extensive metaboliser, <italic>PM</italic> poor metaboliser</p></caption><graphic xlink:href="535_2013_925_Fig3_HTML" id="MO3"/></fig></p><p>After 2 and 4&#x000a0;weeks of PPI therapy, the proportion of patients achieving sufficient relief of their reflux symptoms was similar in the omeprazole 20&#x000a0;mg and rabeprazole 10&#x000a0;mg groups overall (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a), and in patients with the homoEM and the heteroEM phenotypes (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b). In patients with the PM phenotype, however, a significantly greater proportion in the omeprazole 20&#x000a0;mg group than in the rabeprazole 10&#x000a0;mg group achieved sufficient relief of their reflux symptoms after 2&#x000a0;weeks (78.3 vs 42.1&#x000a0;%; <italic>p</italic>&#x000a0;=&#x000a0;0.016) and 4&#x000a0;weeks (95.7 vs 68.4&#x000a0;%; <italic>p</italic>&#x000a0;=&#x000a0;0.018) of PPI therapy (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Proportion of patients achieving sufficient relief of their reflux symptoms (GOS scale score of 1 or 2) after 2 and 4&#x000a0;weeks of therapy with omeprazole 20&#x000a0;mg or rabeprazole 10&#x000a0;mg <bold>a</bold> overall and <bold>b</bold> according to CYP2C19 phenotype. CYP2C19 phenotype was unknown for two patients in the omeprazole group. <italic>CYP2C19</italic> cytochrome P450 2C19, <italic>GOS</italic> Global Overall Symptom, <italic>heteroEM</italic> hetero extensive metaboliser, <italic>homoEM</italic> homo extensive metaboliser, <italic>PM</italic> poor metaboliser</p></caption><graphic xlink:href="535_2013_925_Fig4_HTML" id="MO4"/></fig></p><p>Complete resolution of reflux symptoms was achieved in a significantly greater proportion of patients in the omeprazole 20&#x000a0;mg than in the rabeprazole 10&#x000a0;mg group after both 2&#x000a0;weeks (44.0 vs 27.1&#x000a0;%; <italic>p</italic>&#x000a0;=&#x000a0;0.013) and 4&#x000a0;weeks (55.0 vs 36.5&#x000a0;%; <italic>p</italic>&#x000a0;=&#x000a0;0.009) of PPI therapy (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a). When assessed by CYP2C19 phenotype, a significantly greater proportion of patients with the heteroEM phenotype in the omeprazole 20&#x000a0;mg than in the rabeprazole 10&#x000a0;mg group achieved complete reflux symptom resolution after 2&#x000a0;weeks of PPI therapy (43.6 vs 20.0&#x000a0;%; <italic>p</italic>&#x000a0;=&#x000a0;0.024), but there was no significant difference after 4&#x000a0;weeks of therapy (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b). No significant inter-group difference in this measure was noted at either time point for patients with the homoEM or PM phenotype (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b).<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Proportion of patients achieving complete resolution (GOS scale score of 1) of their reflux symptoms after 2 and 4&#x000a0;weeks of therapy with omeprazole 20&#x000a0;mg or rabeprazole 10&#x000a0;mg <bold>a</bold> overall and <bold>b</bold> according to CYP2C19 phenotype. CYP2C19 phenotype was unknown for two patients in the omeprazole group. <italic>CYP2C19</italic> cytochrome P450 2C19, <italic>GOS</italic> Global Overall Symptom, <italic>heteroEM</italic> hetero extensive metaboliser, <italic>homoEM</italic> homo extensive metaboliser, <italic>PM</italic> poor metaboliser</p></caption><graphic xlink:href="535_2013_925_Fig5_HTML" id="MO5"/></fig></p><p>For upper gastrointestinal symptoms, sufficient relief after 2 and 4&#x000a0;weeks of PPI therapy was similar in the omeprazole 20&#x000a0;mg and rabeprazole 10&#x000a0;mg groups overall, and in patients with the homoEM and the heteroEM phenotypes (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). In patients with the PM phenotype, a significantly greater proportion in the omeprazole 20&#x000a0;mg group than in the rabeprazole 10&#x000a0;mg group achieved sufficient relief of their upper gastrointestinal symptoms after 2&#x000a0;weeks (73.9 vs 26.3&#x000a0;%; <italic>p</italic>&#x000a0;=&#x000a0;0.002), but differences were not statistically significant after 4&#x000a0;weeks (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>b).<fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>Proportion of patients achieving sufficient relief (GOS scale score of 1 or 2) of their upper gastrointestinal symptoms after 2 and 4&#x000a0;weeks of therapy with omeprazole 20&#x000a0;mg or rabeprazole 10&#x000a0;mg <bold>a</bold> overall and <bold>b</bold> according to CYP2C19 phenotype. CYP2C19 phenotype was unknown for two patients in the omeprazole group. <italic>CYP2C19</italic> cytochrome P450 2C19, <italic>GOS</italic> Global Overall Symptom, <italic>heteroEM</italic> hetero extensive metaboliser, <italic>homoEM</italic> homo extensive metaboliser, <italic>PM</italic> poor metaboliser</p></caption><graphic xlink:href="535_2013_925_Fig6_HTML" id="MO6"/></fig></p><p>Complete resolution of upper gastrointestinal symptoms was achieved in a significantly greater proportion of patients in the omeprazole 20&#x000a0;mg group than in the rabeprazole 10&#x000a0;mg group after 4&#x000a0;weeks of PPI therapy (37.0 vs 20.8&#x000a0;%; <italic>p</italic>&#x000a0;=&#x000a0;0.013), but differences were not statistically significant at the earlier, 2-week time point (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a). When assessed according to CYP2C19 polymorphism, a significantly greater proportion of patients with the PM phenotype in the omeprazole 20&#x000a0;mg group than in the rabeprazole 10&#x000a0;mg group achieved complete resolution of their upper gastrointestinal symptoms after 4&#x000a0;weeks of PPI therapy (34.8 vs 21.1&#x000a0;%; <italic>p</italic>&#x000a0;=&#x000a0;0.033), but no significant difference was observed at the earlier, 2-week time point (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>b).<fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>Proportion of patients achieving complete resolution (GOS scale score of 1) of their upper gastrointestinal symptoms after 2 and 4&#x000a0;weeks of therapy with omeprazole 20&#x000a0;mg or rabeprazole 10&#x000a0;mg <bold>a</bold> overall and <bold>b</bold> according to CYP2C19 phenotype was unknown for two patients in the omeprazole group. <italic>CYP2C19</italic> cytochrome P450 2C19, <italic>GOS</italic> Global Overall Symptom, <italic>heteroEM</italic> hetero extensive metaboliser, <italic>homoEM</italic> homo extensive metaboliser, <italic>PM</italic> poor metaboliser</p></caption><graphic xlink:href="535_2013_925_Fig7_HTML" id="MO7"/></fig></p></sec></sec><sec id="Sec16"><title>Safety</title><p>Four adverse events (one each of itching, abdominal fullness, thirst and rash/exanthema) were reported in four patients treated with omeprazole 20&#x000a0;mg, of whom three had the homoEM and one the PM phenotype. All adverse events were considered by the investigator to be related to the study drug but none were graded as being serious. No adverse events were recorded for patients treated with rabeprazole 10&#x000a0;mg.</p></sec></sec><sec id="Sec17" sec-type="discussion"><title>Discussion</title><p>In this 4-week, randomised study in Japanese patients with endoscopically confirmed reflux esophagitis, omeprazole 20&#x000a0;mg once daily was significantly more effective than rabeprazole 10&#x000a0;mg once daily at achieving early, sufficient, and sustained reflux symptom relief. On both day 1 and day 2 of PPI therapy, the proportion of patients achieving sufficient and sustained reflux symptom relief was at least 50&#x000a0;% higher in the omeprazole 20&#x000a0;mg group than in the rabeprazole 10&#x000a0;mg group. The study thus met its primary efficacy endpoint of early onset of sufficient and sustained relief of reflux symptoms, defined as the first day of sufficient reflux symptom relief that was maintained for at least 7 consecutive days. Furthermore, a significantly greater proportion of patients achieved complete resolution of their reflux symptoms with omeprazole 20&#x000a0;mg than with rabeprazole 10&#x000a0;mg at both 2 and 4&#x000a0;weeks of PPI therapy, and a significantly greater proportion of patients treated with omeprazole 20&#x000a0;mg also experienced complete resolution of upper gastrointestinal symptoms after 4&#x000a0;weeks of PPI therapy.</p><p>The pharmacodynamics and pharmacokinetics of PPIs are affected by genetic polymorphisms of CYP2C19, such that intragastric pH and plasma PPI levels are highest in patients with the PM phenotype, lowest in those with the homoEM phenotype and intermediate in those with the heteroEM phenotype [<xref ref-type="bibr" rid="CR13">13</xref>]. Given that the PM phenotype is particularly prevalent in the Japanese population [<xref ref-type="bibr" rid="CR13">13</xref>], we also evaluated outcomes based on CYP2C19 phenotype. At baseline, 21&#x000a0;% of patients in our study were shown to have the PM phenotype, which is consistent with the prevalence for this trait in the general Japanese population (18.0&#x02013;22.5&#x000a0;%) [<xref ref-type="bibr" rid="CR13">13</xref>]. Our study showed that omeprazole 20&#x000a0;mg was also more effective than rabeprazole 10&#x000a0;mg at relieving and resolving reflux symptoms in patients with the PM phenotype; indeed, the proportion of patients achieving sufficient and sustained reflux symptom relief was at least 65&#x000a0;% higher in the omeprazole 20&#x000a0;mg group than in the rabeprazole 10&#x000a0;mg group in patients with the PM phenotype on days 1&#x02013;7 of PPI therapy, and this difference reached statistical significance on days 4&#x02013;7. Reflux symptom relief remained significantly more effective with omeprazole 20&#x000a0;mg than with rabeprazole 10&#x000a0;mg at 2 and 4&#x000a0;weeks of PPI therapy in patients with the PM phenotype.</p><p>These results are consistent with the finding that CYP2C19 phenotype status has a greater effect on the pharmacokinetics of omeprazole than on the pharmacokinetics of rabeprazole, with a greater difference in systemic exposure to omeprazole than to rabeprazole seen across CYP2C19 phenotype categories [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Although, by inference, it might be expected that systemic exposure to omeprazole is reduced in heteroEM and particularly homoEM phenotype patients, and this might translate into a decline in efficacy, our study did not show any significant differences in reflux-related outcomes favouring rabeprazole in these subgroups.</p><p>In line with these findings, results from a study conducted in healthy Japanese volunteers showed that early acid inhibition (measured by gastric pH) was greater after omeprazole 20&#x000a0;mg than after rabeprazole 10&#x000a0;mg in a combined group of heteroEM and PM phenotypes, but not in homoEM phenotypes, although this significant difference did not persistent after 1&#x000a0;week of PPI therapy [<xref ref-type="bibr" rid="CR17">17</xref>]. The results from our study suggest that these early differences in acid inhibition translate into improved, early reflux symptom relief with omeprazole 20&#x000a0;mg, compared with rabeprazole 10&#x000a0;mg, in patients with reflux esophagitis and the PM phenotype. However, early differences in acid inhibition seen with omeprazole 20&#x000a0;mg versus rabeprazole 10&#x000a0;mg in healthy volunteers with the homoEM or heteroEM phenotypes [<xref ref-type="bibr" rid="CR15">15</xref>] may not translate into differences in early reflux symptom relief with the two PPIs. In our study, omeprazole 20&#x000a0;mg and rabeprazole 10&#x000a0;mg were broadly similarly effective at relieving and resolving reflux symptoms in patients with the homoEM and heteroEM phenotypes, with no significant differences observed at any of the time points analysed. Results from a multinational study conducted in Europe (where the prevalence of the PM phenotype is &#x02264;3.7&#x000a0;% [<xref ref-type="bibr" rid="CR13">13</xref>]) showed a median time to heartburn relief of 1.5&#x000a0;days for both omeprazole 20&#x000a0;mg and rabeprazole 20&#x000a0;mg in patients with reflux esophagitis, suggesting that the two PPIs are similarly effective at early symptom relief in a population with predominantly homoEM and heteroEM phenotypes, even when the higher dose of 20&#x000a0;mg rabeprazole is used [<xref ref-type="bibr" rid="CR22">22</xref>]. Correspondingly, in another study conducted in Europe, decreases in 24-h esophageal acid exposure in response to PPI therapy in patients with GERD were similar with omeprazole 20&#x000a0;mg and rabeprazole 20&#x000a0;mg [<xref ref-type="bibr" rid="CR24">24</xref>]. Taking into account the distribution of the different CYP2C19 phenotypes and the treatment doses, we consider it reasonable to expect that omeprazole 20&#x000a0;mg might be more effective than rabeprazole 10&#x000a0;mg at treating symptoms in Japanese patients with reflux esophagitis.</p><p>In addition to the typical symptoms of GERD (heartburn and acid regurgitation), patients with GERD commonly experience other upper gastrointestinal symptoms, including bloating, belching and abdominal pain [<xref ref-type="bibr" rid="CR25">25</xref>]. Typical symptoms of GERD and dyspepsia-related symptoms often occur together, even in uninvestigated patients. Upper gastrointestinal symptoms have been shown to improve with PPI therapy [<xref ref-type="bibr" rid="CR19">19</xref>]. The objective of our study was to evaluate improvement of symptoms in patients with reflux esophagitis, and the GOS scale, which measures upper gastrointestinal symptoms, was considered to be the appropriate questionnaire for this aim. When assessing a combination of eight upper gastrointestinal symptoms in this study, a significantly greater proportion of patients in the omeprazole 20&#x000a0;mg group than in the rabeprazole 10&#x000a0;mg group experienced complete symptom resolution at 4&#x000a0;weeks of PPI therapy. In patients with the PM phenotype, omeprazole 20&#x000a0;mg showed a significantly higher efficacy than rabeprazole 10&#x000a0;mg at relieving (at 2&#x000a0;weeks) and resolving (at 4&#x000a0;weeks) upper gastrointestinal symptoms. Furthermore, omeprazole 20&#x000a0;mg and rabeprazole 10&#x000a0;mg were broadly similarly effective at relieving and resolving these symptoms in patients with the homoEM and heteroEM phenotypes. Our results therefore suggest that improved early symptom relief with omeprazole 20&#x000a0;mg, compared with rabeprazole 10&#x000a0;mg, in patients with reflux esophagitis and the PM phenotype applies not only to reflux symptoms, but also to other upper gastrointestinal symptoms that are common in GERD.</p><p>Both omeprazole 20&#x000a0;mg and rabeprazole 10&#x000a0;mg were generally well-tolerated in this 4-week study. Only four adverse events were recorded (itching, abdominal fullness, thirst, rash/exanthema), all in patients receiving omeprazole 20&#x000a0;mg. Although the incidence of adverse events was low, there was no evidence of a relationship with the CYP2C19 phenotype.</p><p>Key strengths of our study include the use of a validated patient-reported outcome instrument to record symptoms, the inclusion of patients with endoscopically confirmed reflux esophagitis, the separate analyses according to all three CYP2C19 phenotypes, and the use of study drug doses relevant to clinical practice in Japan. A limitation of our study is the open-label design, which means that confounding of outcomes by treatment expectation cannot be excluded. In addition, the symptomatic improvements seen with omeprazole 20&#x000a0;mg over rabeprazole 10&#x000a0;mg were not corroborated by endoscopic evaluation of reflux esophagitis. Since there has been little published data regarding symptom-based evaluations in early-phase response to treatment in GERD [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>], the primary endpoint of this study was symptom relief in the early phase of treatment rather than mucosal healing, which is why endoscopy was not included in the study protocol. Regarding 4&#x02013;8-week initial therapies for reflux esophagitis, symptom relief was relevant to mucosal healing [<xref ref-type="bibr" rid="CR30">30</xref>]. Although endoscopy should be performed to confirm cure of reflux esophagitis, the fact that many patients achieved sufficient relief of reflux symptoms at 4&#x000a0;weeks in this study indicates that many of them might be cured. Furthermore, although doses of omeprazole 20&#x000a0;mg and rabeprazole 10&#x000a0;mg were consistent with those approved for current clinical practice in Japan, evidence suggests that rabeprazole has a more potent effect on acid suppression than omeprazole on a mg for mg basis [<xref ref-type="bibr" rid="CR31">31</xref>]. It is open to question whether the advantage for omeprazole 20&#x000a0;mg would have been sustained if rabeprazole had been administered at the same dose; however, doses were chosen based on current clinical practice in Japan.</p><p>In conclusion, the results of our study show that omeprazole 20&#x000a0;mg once-daily is significantly more effective than rabeprazole 10&#x000a0;mg once daily at achieving sufficient and sustained relief of reflux symptom in the first 2&#x000a0;days of PPI therapy in Japanese patients with reflux esophagitis. This significant advantage of omeprazole 20&#x000a0;mg therapy also extends to resolution of reflux and upper gastrointestinal symptoms. Omeprazole 20&#x000a0;mg is more effective than rabeprazole 10&#x000a0;mg at early relief and resolution of reflux symptoms and other upper gastrointestinal symptoms in patients with the PM phenotype, and has similar effectiveness to rabeprazole 10&#x000a0;mg in patients with the heteroEM and homoEM phenotypes. These findings can assist physicians with disease management in patients with reflux esophagitis in Japan, where the PM phenotype is much more common than in the USA or Europe [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec></body><back><ack><p>We would like to thank the following study investigators: Kiyoharu Ito (Ozaki Clinic), Tetsuya Murao (Ozaki Clinic), Satoshi Yamada (Yamada Clinic), Akihiko Kurosawa (Kurosawa Gastroenterological Clinic), Toshio Murai (Murai Clinic), Yukihiro Sakurai (Sakurai Digestive Disease Clinic), Shuhei Tazaki (Tazaki Clinic) and Ryuzo Murai (Onaka Clinic).</p><sec id="d30e2350"><title>Conflict of interest</title><p>The authors declare that they have no conflict of interest.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnellan</surname><given-names>C</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Preston</surname><given-names>C</given-names></name><name><surname>Moayyedi</surname><given-names>P</given-names></name></person-group><article-title>Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease</article-title><source>Cochrane Database Syst Rev</source><year>2005</year><volume>2</volume><fpage>CD003245</fpage><pub-id pub-id-type="pmid">15846653</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vakil</surname><given-names>N</given-names></name><name><surname>Veldhuyzen van Zanten</surname><given-names>S</given-names></name><name><surname>Kahrilas</surname><given-names>P</given-names></name><name><surname>Dent</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name></person-group><article-title>The Montreal definition and classification of gastro-esophageal reflux disease (GERD)&#x02014;a global evidence-based consensus</article-title><source>Am J Gastroenterol</source><year>2006</year><volume>101</volume><fpage>1900</fpage><lpage>1920</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2006.00630.x</pub-id><pub-id pub-id-type="pmid">16928254</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kinoshita</surname><given-names>Y</given-names></name><name><surname>Adachi</surname><given-names>K</given-names></name><name><surname>Hongo</surname><given-names>M</given-names></name><name><surname>Haruma</surname><given-names>K</given-names></name></person-group><article-title>Systematic review of the epidemiology of gastroesophageal reflux disease in Japan</article-title><source>J Gastroenterol</source><year>2011</year><volume>46</volume><fpage>1092</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1007/s00535-011-0429-3</pub-id><pub-id pub-id-type="pmid">21695373</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuki</surname><given-names>N</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>N</given-names></name><etal/></person-group><article-title>Lifestyle factors associated with gastroesophageal reflux disease in the Japanese population</article-title><source>J Gastroenterol</source><year>2013</year><volume>48</volume><fpage>340</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1007/s00535-012-0649-1</pub-id><pub-id pub-id-type="pmid">22911169</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronkainen</surname><given-names>J</given-names></name><name><surname>Aro</surname><given-names>P</given-names></name><name><surname>Storskrubb</surname><given-names>T</given-names></name><etal/></person-group><article-title>Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population&#x02014;the Kalixanda study</article-title><source>Aliment Pharmacol Ther</source><year>2006</year><volume>23</volume><fpage>1725</fpage><lpage>1733</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.02952.x</pub-id><pub-id pub-id-type="pmid">16817916</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahlqvist</surname><given-names>P</given-names></name><name><surname>Reilly</surname><given-names>M</given-names></name><name><surname>Barkun</surname><given-names>AN</given-names></name></person-group><article-title>Systematic review: the impact of gastro-oesophageal reflux disease on work productivity</article-title><source>Aliment Pharmacol Ther</source><year>2006</year><volume>24</volume><fpage>259</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.02996.x</pub-id><pub-id pub-id-type="pmid">16842452</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahlqvist</surname><given-names>P</given-names></name><name><surname>Karlsson</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>D</given-names></name><name><surname>Carlsson</surname><given-names>J</given-names></name><name><surname>Bolge</surname><given-names>S</given-names></name><name><surname>Wallander</surname><given-names>MA</given-names></name></person-group><article-title>Relationship between symptoms of gastroesophageal reflux disease and costs: a database study in a US cohort</article-title><source>Value Health</source><year>2007</year><volume>10</volume><fpage>A149</fpage><pub-id pub-id-type="doi">10.1016/S1098-3015(10)68993-0</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiklund</surname><given-names>I</given-names></name><name><surname>Carlsson</surname><given-names>J</given-names></name><name><surname>Vakil</surname><given-names>N</given-names></name></person-group><article-title>Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community</article-title><source>Am J Gastroenterol</source><year>2006</year><volume>101</volume><fpage>18</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2005.00343.x</pub-id><pub-id pub-id-type="pmid">16405529</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronkainen</surname><given-names>J</given-names></name><name><surname>Talley</surname><given-names>NJ</given-names></name><name><surname>Storskrubb</surname><given-names>T</given-names></name><etal/></person-group><article-title>Erosive esophagitis is a risk factor for Barrett&#x02019;s esophagus: a community-based endoscopic follow-up study</article-title><source>Am J Gastroenterol</source><year>2011</year><volume>106</volume><fpage>1946</fpage><lpage>1952</lpage><pub-id pub-id-type="doi">10.1038/ajg.2011.326</pub-id><pub-id pub-id-type="pmid">21946284</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Pinxteren</surname><given-names>B</given-names></name><name><surname>Numans</surname><given-names>ME</given-names></name><name><surname>Bonis</surname><given-names>PA</given-names></name><name><surname>Lau</surname><given-names>J</given-names></name></person-group><article-title>Short-term treatment with proton pump inhibitors, H<sub>2</sub>-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease</article-title><source>Cochrane Database Syst Rev</source><year>2004</year><volume>4</volume><fpage>CD002095</fpage><pub-id pub-id-type="pmid">15495027</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulig</surname><given-names>M</given-names></name><name><surname>Leodolter</surname><given-names>A</given-names></name><name><surname>Vieth</surname><given-names>M</given-names></name><etal/></person-group><article-title>Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease&#x02014;an analysis based on the ProGERD initiative</article-title><source>Aliment Pharmacol Ther</source><year>2003</year><volume>18</volume><fpage>767</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2003.01770.x</pub-id><pub-id pub-id-type="pmid">14535869</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pace</surname><given-names>F</given-names></name><name><surname>Negrini</surname><given-names>C</given-names></name><name><surname>Wiklund</surname><given-names>I</given-names></name><name><surname>Rossi</surname><given-names>C</given-names></name><name><surname>Savarino</surname><given-names>V</given-names></name></person-group><article-title>Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease</article-title><source>Aliment Pharmacol Ther</source><year>2005</year><volume>22</volume><fpage>349</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2005.02558.x</pub-id><pub-id pub-id-type="pmid">16098002</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>M</given-names></name><name><surname>Shirai</surname><given-names>N</given-names></name><name><surname>Ishizaki</surname><given-names>T</given-names></name></person-group><article-title>CYP2C19 pharmacogenomics associated with therapy of <italic>Helicobacter pylori</italic> infection and gastro-esophageal reflux diseases with a proton pump inhibitor</article-title><source>Pharmacogenomics</source><year>2007</year><volume>8</volume><fpage>1199</fpage><lpage>1210</lpage><pub-id pub-id-type="doi">10.2217/14622416.8.9.1199</pub-id><pub-id pub-id-type="pmid">17924835</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirai</surname><given-names>N</given-names></name><name><surname>Furuta</surname><given-names>T</given-names></name><name><surname>Moriyama</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH</article-title><source>Aliment Pharmacol Ther</source><year>2001</year><volume>15</volume><fpage>1929</fpage><lpage>1937</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2001.01108.x</pub-id><pub-id pub-id-type="pmid">11736724</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saitoh</surname><given-names>T</given-names></name><name><surname>Fukushima</surname><given-names>Y</given-names></name><name><surname>Otsuka</surname><given-names>H</given-names></name><etal/></person-group><article-title>Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers</article-title><source>Aliment Pharmacol Ther</source><year>2002</year><volume>16</volume><fpage>1811</fpage><lpage>1817</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2002.01348.x</pub-id><pub-id pub-id-type="pmid">12269976</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamagishi</surname><given-names>H</given-names></name><name><surname>Koike</surname><given-names>T</given-names></name><name><surname>Ohara</surname><given-names>S</given-names></name><etal/></person-group><article-title>Early effects of Lansoprazole orally disintegrating tablets on intragastric pH in CYP2C19 extensive metabolizers</article-title><source>World J Gastroenterol</source><year>2008</year><volume>14</volume><fpage>2049</fpage><lpage>2054</lpage><pub-id pub-id-type="doi">10.3748/wjg.14.2049</pub-id><pub-id pub-id-type="pmid">18395905</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>K</given-names></name><name><surname>Adachi</surname><given-names>K</given-names></name><name><surname>Ohara</surname><given-names>S</given-names></name><etal/></person-group><article-title>Relationship between the acid-inhibitory effects of two proton pump inhibitors and CYP2C19 genotype in Japanese subjects: a randomized two-way crossover study</article-title><source>J Int Med Res</source><year>2010</year><volume>38</volume><fpage>1473</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1177/147323001003800430</pub-id><pub-id pub-id-type="pmid">20926021</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldhuyzen Van Zanten</surname><given-names>SJ</given-names></name><name><surname>Chiba</surname><given-names>N</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><etal/></person-group><article-title>Validation of a 7-point global overall symptom scale to measure the severity of dyspepsia symptoms in clinical trials</article-title><source>Aliment Pharmacol Ther</source><year>2006</year><volume>23</volume><fpage>521</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.02774.x</pub-id><pub-id pub-id-type="pmid">16441473</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>K</given-names></name><name><surname>Nagahara</surname><given-names>A</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><etal/></person-group><article-title>Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS)</article-title><source>BMC Gastroenterol</source><year>2012</year><volume>12</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1186/1471-230X-12-42</pub-id><pub-id pub-id-type="pmid">22548767</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veldhuyzen van Zanten</surname><given-names>S</given-names></name><name><surname>Armstrong</surname><given-names>D</given-names></name><name><surname>Chiba</surname><given-names>N</given-names></name><etal/></person-group><article-title>Esomeprazole 40&#x000a0;mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled &#x0201c;ENTER&#x0201d; trial</article-title><source>Am J Gastroenterol</source><year>2006</year><volume>101</volume><fpage>2096</fpage><lpage>2106</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2006.00751.x</pub-id><pub-id pub-id-type="pmid">16817845</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewan</surname><given-names>B</given-names></name><name><surname>Philipose</surname><given-names>N</given-names></name></person-group><article-title>Lafutidine 10&#x000a0;mg versus rabeprazole 20 mg in the treatment of patients with heartburn-dominant uninvestigated dyspepsia: a randomized, multicentric trial</article-title><source>Gastroenterol Res Pract</source><year>2011</year><volume>2011</volume><fpage>640685</fpage><pub-id pub-id-type="doi">10.1155/2011/640685</pub-id><pub-id pub-id-type="pmid">21687618</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bytzer</surname><given-names>P</given-names></name><name><surname>Morocutti</surname><given-names>A</given-names></name><name><surname>Kennerly</surname><given-names>P</given-names></name><name><surname>Ravic</surname><given-names>M</given-names></name><name><surname>Miller</surname><given-names>N</given-names></name></person-group><article-title>Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment</article-title><source>Scand J Gastroenterol</source><year>2006</year><volume>41</volume><fpage>1132</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1080/00365520600615781</pub-id><pub-id pub-id-type="pmid">16990197</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>T</given-names></name><name><surname>Ohashi</surname><given-names>K</given-names></name><name><surname>Kosuge</surname><given-names>K</given-names></name><etal/></person-group><article-title>CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans</article-title><source>Clin Pharmacol Ther</source><year>1999</year><volume>65</volume><fpage>552</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1016/S0009-9236(99)70075-5</pub-id><pub-id pub-id-type="pmid">10340921</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galmiche</surname><given-names>JP</given-names></name><name><surname>Zerbib</surname><given-names>F</given-names></name><name><surname>Ducrott&#x000e8;</surname><given-names>P</given-names></name><etal/></person-group><article-title>Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole</article-title><source>Aliment Pharmacol Ther</source><year>2001</year><volume>15</volume><fpage>1343</fpage><lpage>1350</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2001.01030.x</pub-id><pub-id pub-id-type="pmid">11552904</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vakil</surname><given-names>N</given-names></name><name><surname>Halling</surname><given-names>K</given-names></name><name><surname>Wernersson</surname><given-names>B</given-names></name><name><surname>Ohlsson</surname><given-names>L</given-names></name></person-group><article-title>Rome III functional dyspepsia criteria show substantial symptom overlap with gastroesophageal reflux disease</article-title><source>Gut</source><year>2011</year><volume>60</volume><issue>Suppl 3</issue><fpage>A154</fpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fock</surname><given-names>KM</given-names></name><name><surname>Teo</surname><given-names>EK</given-names></name><name><surname>Ang</surname><given-names>TL</given-names></name><name><surname>Chua</surname><given-names>TS</given-names></name><name><surname>Ng</surname><given-names>TM</given-names></name><name><surname>Tan</surname><given-names>YL</given-names></name></person-group><article-title>Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia</article-title><source>World J Gastroenterol</source><year>2005</year><volume>11</volume><fpage>3091</fpage><lpage>3098</lpage><pub-id pub-id-type="pmid">15918196</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archimandritis</surname><given-names>AJ</given-names></name><name><surname>Nikolopoulou</surname><given-names>V</given-names></name><name><surname>Kouklakis</surname><given-names>G</given-names></name><name><surname>Paraskevas</surname><given-names>E</given-names></name><name><surname>Avgerinos</surname><given-names>A</given-names></name><name><surname>Tsianos</surname><given-names>E</given-names></name><name><surname>Triantafillidis</surname><given-names>JK</given-names></name><collab>Hellenic Rabeprazole Study Group</collab></person-group><article-title>Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study</article-title><source>Curr Med Res Opin</source><year>2005</year><volume>21</volume><fpage>603</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1185/030079905X41444</pub-id><pub-id pub-id-type="pmid">15899110</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mee</surname><given-names>AS</given-names></name><name><surname>Rowley</surname><given-names>JL</given-names></name></person-group><article-title>Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole</article-title><source>Aliment Pharmacol Ther</source><year>1996</year><volume>10</volume><fpage>757</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.1996.56198000.x</pub-id><pub-id pub-id-type="pmid">8899084</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tominaga</surname><given-names>K</given-names></name><name><surname>Iwakiri</surname><given-names>R</given-names></name><name><surname>Fujimoto</surname><given-names>K</given-names></name><collab>GERD 4 Study Group</collab><etal/></person-group><article-title>Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan</article-title><source>J Gastroenterol</source><year>2012</year><volume>47</volume><fpage>284</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1007/s00535-011-0488-5</pub-id><pub-id pub-id-type="pmid">22081052</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>M</given-names></name><name><surname>Santana</surname><given-names>J</given-names></name><name><surname>Donnellan</surname><given-names>C</given-names></name><name><surname>Preston</surname><given-names>C</given-names></name><name><surname>Moayyedi</surname><given-names>P</given-names></name></person-group><article-title>Medical treatments in the short term management of reflux oesophagitis</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><volume>2</volume><fpage>CD003244</fpage><pub-id pub-id-type="pmid">17443524</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stedman</surname><given-names>CA</given-names></name><name><surname>Barclay</surname><given-names>ML</given-names></name></person-group><article-title>Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors</article-title><source>Aliment Pharmacol Ther</source><year>2000</year><volume>14</volume><fpage>963</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2000.00788.x</pub-id><pub-id pub-id-type="pmid">10930890</pub-id></element-citation></ref></ref-list></back></article>